Kathleen Glaub, has served as Chief Executive Officer at Afferent Pharmaceuticals, Inc. since September 2014. Afferent develops clinical-stage biotechnology treatments for respiratory and urologic disorders and chronic pain. From 2001 - 20013 Ms. Glaub co-led Plexxicon, Inc., as President. There she managed the successful FDA approval for Zelboraf, the melanoma fighting drug; created a number of lucrative partnership deals with companies like swiss giant Roche and then ultimately structured a buy-out deal with japanese Daiichi-Sankyo for a record billion dollars. That same year, 2011 Kathy was recognized as one of Fierce Biotech’s top women in Biotech. She has over 30 years of management and company-building experience for biopharma and innovation-based companies. She received a BA from the University of California, Berkeley and an MBA in finance from Northwestern University.

Bioengineering 200, 001 - Spring 2014 Creative Commons 3.0: Attribution-NonCommercial-NoDerivs